Macrophages represent a critical cell type in the pathogenesis of chronic inflammatory cardiometabolic diseases, such as atherosclerosis, central obesity, and insulin resistance. The differentiation of human induced pluripotent stem cells (iPSCs) to macrophages (iPSC-derived macrophages [IPSDM]) offers a powerful platform to study human macrophage biology with enormous potential in disease modeling, functional genomic analyses, drug screening, and cell therapeutics. The goal of this brief review is to provide a concise but comprehensive overview of new advances in the differentiation and application of IPSDM, with a major focus on cardiovascular research, while also highlighting cutting edge applications across the vast landscape of macrophage biology in health and diseases (Figure 1).

Visual Overview—An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2017;37:2000-2006. DOI: 10.1161/ATVBAHA.117.309195.)

Key Words: coronary artery disease ◼ genome-wide association study ◼ hematopoiesis ◼ induced pluripotent stem cells ◼ macrophages

Human induced pluripotent stem cell (iPSC)–derived macrophages (IPSDM), as an unlimited source of subject genotype-specific cells, will undoubtedly play an important role in advancing our understanding of the role of macrophages in human diseases. In this review, we summarize current literature in the differentiation and characterization of IPSDM at phenotypic, functional, and transcriptomic levels. We emphasize the progress in differentiating iPSC to tissue resident macrophages, and in understanding the ontogeny of in vitro differentiated IPSDM that resembles primitive hematopoiesis, rather than adult definitive hematopoiesis. We review the application of IPSDM in modeling both Mendelian genetic disorders and host–pathogen interactions. Finally, we highlighted the potential areas of research using IPSDM in functional validation of coronary artery disease loci in genome-wide association studies, functional genomic analyses, drug testing, and cell therapeutics in cardiovascular diseases.

M

icrophages represent a critical cell type in the pathogenesis of chronic inflammatory cardiometabolic diseases, such as atherosclerosis, central obesity, and insulin resistance. The differentiation of human induced pluripotent stem cells (iPSCs) to macrophages (iPSC-derived macrophages [IPSDM]) offers a powerful platform to study human macrophage biology with enormous potential in disease modeling, functional genomic analyses, drug screening, and cell therapeutics. The goal of this brief review is to provide a concise but comprehensive overview of new advances in the differentiation and application of IPSDM, with a major focus on cardiovascular research, while also highlighting cutting edge applications across the vast landscape of macrophage biology in health and diseases (Figure 1).
Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cas9</td>
<td>CRISPR–associated 9</td>
</tr>
<tr>
<td>CRISPR</td>
<td>clustered regularly interspaced short palindromic repeats</td>
</tr>
<tr>
<td>EB</td>
<td>embryoid body</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>granulocyte macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>HMDM</td>
<td>human monocyte-derived macrophages</td>
</tr>
<tr>
<td>IPSC</td>
<td>induced pluripotent stem cell</td>
</tr>
<tr>
<td>IPSDM</td>
<td>iPSC-derived macrophages</td>
</tr>
<tr>
<td>M-CSF</td>
<td>macrophage colony-stimulating factor</td>
</tr>
</tbody>
</table>

HMDM, THP-1 derived macrophages (THP-1Φ) have unlimited replicative potential but are karyotypically abnormal and functionally immature. Tissue macrophages, especially those from healthy subjects, have extremely limited availability. HMDM are relatively easy to obtain, but are difficult to be genetically manipulated, and do not self-renew limiting scalability. IPSDM provides a genotype-specific, scalable, and renewable source of human macrophage that are amenable to genetic manipulation by clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat–associated 9 (CRISPR/Cas9)–mediated gene editing. With continual improvement in differentiation efficiency and fidelity, IPSDM is emerging as a powerful tool in multiple areas of research for disease modeling and more recently, drug testing and cell therapeutics.

Generation, Functional Feature and Molecular Profiling of IPSDM

Multiple protocols have been described to differentiate iPSC into macrophages. The first 2 IPSDM differentiation protocols published by Choi et al9 and Senju et al10 in 2011 used coculture of iPSC with OP9 mouse stromal cell monolayers to induce hematopoietic differentiation, followed by expansion of multipotent myeloid progenitors and differentiation into macrophages with GM-CSF (granulocyte macrophage colony-stimulating factor)9 or M-CSF (macrophage colony-stimulating factor)9,10. In 2013, modified from a protocol published by Karlsson et al11 for human embryonic stem cell to macrophage differentiation, van Wilgenburg et al12 established an embryoid bodies (EBs)-based protocol for IPSDM differentiation in which hematopoiesis was induced under serum-free condition followed by directed differentiation to macrophages with M-CSF either in serum-free media or in media with serum. Yanagimachi et al13 developed a monolayer-based protocol by culturing iPSC on a layer of extracellular matrix component under serum-free condition and differentiated floating monocyte-like cells to macrophage in media with serum and M-CSF. In 2015, our group14 published an EB-based differentiation protocol and for the first time performed transcriptomic characterization using deep RNA-sequencing in HMDM and IPSDM lines derived from the same subjects. The results highlighted the transcriptome similarity between HMDM and IPSDM with a small percentage of genes (12%) differentially expressed. Further, more sophisticated functional characteristics, such as cholesterol efflux, cholesteryl ester hydrolysis, and cytokine secretion profile in macrophages with M1 (lipopolysaccharide+interferon-γ) and M2 (interleukin-4) activation, were compared between multiple HMDM and IPSDM lines and have demonstrated

---

Figure 1. Current status of and future directions for differentiation and application of human induced pluripotent stem cell–derived macrophages (IPSDM). Current IPSDM differentiation protocols use coculture, embryoid body (EB)- or monolayer-based approaches to produce myeloid progenitors and use M-CSF (macrophage colony-stimulating factor) for directed differentiation to mature macrophages. Several macrophage functional features have been characterized, including morphology, surface receptor expression, lipid uptake, phagocytosis, cholesterol efflux, cholesteryl ester (CE) hydrolysis, cytokine secretion, response to stimuli, etc, often in direct comparison with human monocyte-derived macrophages (HMDM). Transcriptome landscape, including alternative splicing events and lncRNA profile, also has been analyzed comprehensively. Emerging evidence supports that in vitro IPSDM differentiation represents primitive hematopoiesis rather than adult definitive hematopoiesis. Protocols for induced pluripotent stem cell (iPSC) differentiation to human and murine microglial-like cells and murine alveolar macrophages have been implemented while other tissue-specific macrophages and organoid culture for tissue engineering remain to be established. IPSDM have been widely used to model Mendelian disorders and host–pathogen interaction. Additional studies to model functional impact of coronary artery diseases (CAD) genome-wide association study (GWAS) loci, epistatic effects, quantitative traits, and gene–environment interaction are being pursued. Use of IPSDM in genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening to discover novel genes and noncoding transcripts regulating human macrophage function, and identify functional regulatory and causal variants holds great promise. Use of IPSDM in drug testing and IPSDM-based cell therapy are emerging. Improvement in the fidelity, reproducibility and scalability of IPSDM differentiation in conjunction with CRISPR/clustered regularly interspaced short palindromic repeat–associated 9 (Cas9) gene editing technologies will further reveal the remarkable potential of IPSDM in multiple areas of functional and translational research in human macrophage biology and pathophysiology. CINCA indicates chronic infantile neurological cutaneous and articular; eQTL, expression quantitative trait loci; hPSC, human induced pluripotent stem cells; and lncRNA, long noncoding RNA. Text in italics indicates potential areas of future research.
remarkable similarity. Two additional studies from our group further elaborated that IPSDM recapitulate important alternative splicing events and long noncoding RNA profiles (article under review) of HMDM during macrophage activation, identifying IPSDM as uniquely suited to study human macrophage-specific transcriptome regulation. These protocols used sequential exposure of iPSC to different cytokines that resemble hematopoietic specification and myeloid expansion, and myelomonocytic cells were harvested for directed differentiation to macrophages with M-CSF. The differentiation efficiency was evaluated differently across studies, but generally these protocols have demonstrated high efficiency and scalability with >10 million IPSDM generated from 1 6-well plate of cultured iPSCs.

Although IPSDM have demonstrated similar phenotypic, functional, and transcriptomic characteristics to HMDM, their ontogeny and identity have not been fully defined and this recently has received further study. It has been recognized that in vitro hematopoietic differentiation of PSCs resembles in vivo primitive hematopoiesis rather than definitive hematopoiesis. Vanhee et al. used a reporter human embryonic stem cell line with MYB-eGFP, a marker for hematopoietic stem cell-dependent hematopoiesis, and confirmed the absence of in vitro generation of MYB+ hematopoietic stem cell during EB-based IPSDM differentiation. The results were further validated in human iPSCs, showing that knockout of MYB in iPSC by CRISPR/Cas9 did not impact IPSTEM differentiation. In contrast, when SP1I and RUNXI, important transcription factors in yolk sac hematopoiesis, were knocked out, iPSCs were unable to produce CD14+ macrophages. Thus, IPSDM may developmentally relate to and be a good model for MYB-independent tissue resident macrophages. Indeed, several iPSC to microglia-like cell differentiation protocols were published this year using cytokines representing the main driver of microglia lineage, coculture with iPSC-derived neurons and astrocytes, or incubating with cytokines derived from those cell types to recapitulate organ-specific cues. Takata et al. has published a protocol that specifically resembles primitive hematopoiesis and yolk sac macrophages for further differentiation into tissue macrophage-like cells by coculture or engraftment. The iPSC-derived microglia-like cells showed transcriptome profile highly similar to that of human adult and fetal microglia, and were clustered together with cultured human microglia and away from HMDM and cultured human hepatic macrophages, supporting their role as a more suitable cellular source of microglia than adult hematopoiesis-derived myeloid cells.

It is also noteworthy that the myelomonocytic cells that emerge from EB culture and are collected for subsequent differentiation to macrophages, indeed originally termed monocytes, are now recognized as MYB-independent primitive myeloid cells that clustered away from peripheral blood monocytes based on their transcriptome profile. We also have performed RNA-sequencing of myeloid progenitors (CD34+CD43+CD45+CD18+) harvested during progressive commitment and maturation to IPSDM and showed that the expression profile of those progenitors is highly correlated to that of IPSDM but not CD14+ monocytes (Figure 2). Thus, successful differentiation of circulating monocytes will rely on a more complete understanding of mechanisms regulating definitive hematopoietic specification and identification of factors governing the generation of hematopoietic stem cells from iPSCs, knowledge gaps that remain major goals of regenerative medicine.

Future studies to further improve efficiency, reproducibility and scalability of IPSDM differentiation with potential for automated differentiation will facilitate the application of IPSDM in multiple areas of research. It has been suggested that the differentiation efficiency and yield are higher when using serum-free media to differentiate EBs into myeloid precursors as opposed to serum-containing media. Monolayer-directed differentiation as opposed to an EB-based differentiation that generates cells of all 3 germ layers may have advantage for differentiation in defined conditions, but direct comparison has not been performed. Novel protocols to differentiate IPSDM to tissue resident macrophages, for example, cardiac macrophages, will further raise the possibilities to delve into their specialized properties and tissue-specific functions. It is
also important to consider whether IPSDM may resemble the heterogeneity of human tissue resident macrophages at single cell levels and the mechanisms driving the heterogeneity and downstream functional consequences.

**Disease Modeling and Functional Genomic Analyses With IPSDM**

IPSDM overcome the limitations of the lack of an adequate supply of disease-specific primary macrophages in studying rare diseases, patients-derived IPSDM are increasingly used to model Mendelian diseases, for example, Tangier disease (mutations in ABCA1), lysosomal storage diseases including neuronal ceroid lipofuscinoses and Gaucher disease (mutations in GBA), chronic granulomatous disease (defective NADPH oxidase), Blau syndrome (mutation in NOD2), and chronic infantile neurological cutaneous and articular syndrome (mutation in NLRP3).

Some of these studies compared the phenotypes of IPSDM and HMDM derived from the same subjects to further validate the fidelity of IPSDM in assessing the functionality of genetic mutations. CRISPR/Cas9 gene editing technologies further expanded the potential by introducing disease mutation in iPSC lines derived from healthy subjects and to correct mutations in the iPSC lines of affected patients to demonstrate causality and the functional impact of the disease mutations on a specific isogenic background.

IPSDM also serves as a powerful tool to study macrophage host–pathogen interaction. IPSDM can be infected with various strains of HIV-1 and support Salmonella and Chlamydia infection. Knockout of IRF5/IL10RA by CRISPR/Cas9 led to increased susceptibility to Chlamydia trachomatis infection in IPSDM. This approach can potentially be extended to study other pathogens to advance our understanding of mechanisms of host–pathogen interactions in macrophages and the role of human genetics in influencing the susceptibility to specific pathogens and outcome of infections.

IPSDM provides a unique platform for functional genomic analyses. To date, genome-wide association studies have identified 73 coronary artery diseases–associated regions. Genome editing in human iPSCs to introduce separately each risk allele, or a combination of alleles, and to correct risk alleles and then differentiate to macrophages allows the interrogation of the macrophage-specific function of the causal variants at genome-wide association study coronary artery disease loci. IPSDM are also powerful tools for modeling genetic interactions, alternative splicing, and macrophage-specific functional noncoding transcripts and regulatory elements. By establishing a biobank of iPSC lines derived from a large number of healthy subjects, one can study gene–environment interaction and map quantitative trait loci under various stimuli to determine how genetic differences between individuals may alter immune cells’ response to environmental stimuli, and whether variation in the response may predict susceptibility or resilience to macrophage-related disorders in humans including atherosclerosis and coronary artery disease. The coculture or 3-dimensional systems, involving IPSDM and other iPSC-derived cell types relevant to atherosclerosis, including endothelial cells and smooth muscle cells, to form 3D tissue-engineered blood vessel organoids, will be crucial to advance in vitro disease modeling, for example, organs on a chip, and better recapitulate the complexity of the tissue-level in vivo environment. The scalability of the IPSDM platform can allow genome-wide CRISPR screening of human macrophage-specific regulatory element or knockout screening to identify novel regulators of functional phenotypes, which to date have only been performed in immortalized cell lines or PSC lines.

**Drug Testing and Cell Therapeutics**

Patient-derived IPSDM-based in vitro assays are starting to impact the drug discovery process. IPSDM derived from Gaucher disease patients because of mutations in GBA, a gene encoding glucocerebrosidase, were used to test the efficacy of a noninhibitory small-molecule chaperone drug previously identified from high-throughput screening of compound libraries to enhance glucocerebrosidase activity and reverse the disease phenotype. IPSDM derived from chronic infantile neurological cutaneous and articular syndrome patients carrying mutations in NLRP3 were used to test existing anti-inflammatory compounds in inhibiting the abnormal IL-1β secretion, and can be potentially used to seek drug candidates that directly modulate NLRP3-inflammasome activation for chronic inflammatory conditions such as atherosclerosis. Beyond the use of patient-derived IPSDM, CRISPR/Cas9-edited IPSDM for key regulators in inflammation and lipid metabolism pathways can be exploited for the development of novel therapeutics and delivery systems.

The development of organoid systems derived from isogenic iPSC lines will allow drug effects to be tested within the context of the symbiotic interactions between macrophages and their host tissue with the potential for development of individualized treatment strategies.

IPSDM-based cell therapeutics have been studied mainly in cancer and airway diseases using murine models particularly relating to the protective benefits of macrophage-mediated phagocytosis. The intraperitoneal injection of iPSC-derived myeloid cells genetically engineered to express interferon-β significantly inhibited the growth of human gastric and pancreatic cancers implanted in the peritoneal cavity, as well as inhibiting the growth of disseminated human melanoma cells in immunocompromised mice.

IPSC-derived primitive macrophages intranasally transferred to the lung matured into alveolar macrophages and eliminated the surfactant protein accumulated as a result of Csf2ra deficiency in mice. Indeed, evidence is emerging that iPSC-derived myeloid cells may have specific advantages as in cell therapeutics. In mice, iPSC-derived primitive macrophages exhibit greater capacity to be differentiated into microglia-like cells by coculturing with neurons than monocytes and bone marrow–derived macrophages. Similarly, murine iPSC-derived alveolar macrophages engraft in lung better than bone marrow–derived macrophages.

Adult mammalian myocardium contains diverse macrophage populations with distinct origins and function. At steady state, the majority of the resident macrophages is derived from yolk sac progenitors and primarily maintained...
through local proliferation. However, during injury, circulating monocytes are recruited, differentiated to macrophages and reside, whereas resident macrophages expand through proliferation. Transcriptional analyses reveal that monocyte-derived macrophages coordinate cardiac inflammation, while playing lesser roles in antigen sampling and effrocytosis. Similarly, embryonic and neonatal macrophages regulate tissue remodeling during development with a lower capacity to generate inflammatory response compared with monocyte-derived macrophages. Therefore, it has been proposed that preserving resident cardiac macrophages expansion, while targeting peripheral monocyte recruitment may lead to improved myocardial recovery after injury. Our RNA-sequencing data suggested that IPSDM may be less inflammatory, as genes expressed at lower levels in IPSDM versus HMDM were enriched in gene ontology terms immune response, antigen processing and presentation, and response to stimulus, but whether IPSDM could exert therapeutic benefits in cardiac injury remains an unexplored question. Deeper understanding of the functions of cardiac-resident macrophages in the steady state and injured heart and macrophage populations in the diseased vasculature, will reveal the potential of IPSDM as a cell therapeutic strategy in cardiovascular diseases. Yet significant challenges and barriers for clinical application of IPSDM and any PSC-based products remain to be addressed.

Limitations and Cautions
Application of iPSC-derived cells for functional genomics and translational studies has many strengths, but current limitations should be considered carefully. These include (1) clonal variability can occur during iPSC reprogramming and has been well recognized to cause variations in differentiation efficiency and the functional properties of differentiated cells. Somatic cell source and reprogramming methods also may affect differentiation efficiency, but the impact on IPSDM has not been systematically evaluated. It is therefore essential to use well-characterized iPSC lines, highly consistent differentiation protocols with quality assessment at multiple stages of the differentiation process, and multiple iPSC lines/clones per subject with independent replications to minimize variability and render statistically significant and meaningful experimental outcomes. (2) The gene of interest and functional phenotypes to be tested in IPSDM need to be carefully chosen and evaluated, for example, whether the target genes or noncoding transcripts show similar expression profile between IPSDM and HMDM, or whether the alternative splicing events or the regulatory features of HMDM are also represented by IPSDM. For initial screening, our studies characterizing the coding genes and lncRNA (long intergenic noncoding RNA) transcriptome (article under review), and alternative splicing events in isogenic IPSDM and HMDM lines provide a powerful resource for planning IPSDM studies to model such events, but specific validation for each chosen target is essential. (3) Some target genes may affect iPSC reprogramming or IPSDM differentiation efficiency, and cannot be reliably studied in IPSDM. Also IPSDM modeling of aging-associated cellular phenotypes has not been established. (4) Carefully designed controls and a combination of experimental strategies are essential for faithful interpretation of the functional consequences of target genes when using IPSDM, for example, patient-derived iPSC lines with correction of disease causing mutations in conjunction with wild-type lines with gene knockout or knockin of the mutations, and CRISPRi- and CRISPRa-mediated gene inhibition and activation and add powerful complementary layers of information. (5) Use of IPSDM does not eliminate the need for traditional cellular models or distinct genetic manipulations, for example, siRNA or antisense oligonucleotides mediated knockdown, which are complementary and alternative approaches to further ensure validity and reproducibility.

Conclusions
IPSDM possess enormous value in advancing our understanding of diseases that involve human macrophages and already have demonstrated proof of principle utility in the development of novel therapies. Future studies will focus on automation of IPSDM differentiation, via both primitive and definitive hematopoiesis, with high scalability and reproducibility to produce the full range of myeloid cells that have tissue-specific properties and are applicable for tissue engineering. In such contexts, IPSDM will be instrumental in validating human genetic discoveries, advancing functional genomics, and facilitating clinical and therapeutic translation for diseases such as atherosclerosis and coronary artery disease in which macrophages play a modulatory role in the clinical outcome.

Sources of Funding
This study is supported by National Institutes of Health (NIH) grants R01-HL-113147 and K24-HL-107643 (to M.P. Reilly), and partially supported by American Heart Association Postdoctoral Fellowship 15POST25620017 and NIH grant K09-HL-130574 (to H. Zhang). M.P. Reilly is also supported by R01-HL-111694 and R01-HL-132561.

Disclosures
None.

References
CRISPR/Cas9-mediated gene editing in human iPSC-derived macrophage

stem cells under partly-defined and fully-defined conditions.
production of monocyte-derived macrophages from human pluripotent
exphem.2008.04.009.

phenotypic characteristics of neuronal cerebral lipofuscinosis. Int J Mol Sci.


27. Uusi-Rauva K, Blom T, van Schantz-Cant F, Blom T, Jalanko A, Kyttala A. Induced pluripotent stem cells derived from a c57 mouse patient
phenotypic characteristics of neuronal cerebral lipofuscinosis. Int J Mol Sci.


29. Afaki E, Stubblefield BK, Maniwpang E, Lopez G, Moaven N, Goldin E,


The differentiation of human induced pluripotent stem cells to macrophages (induced pluripotent stem cell–derived macrophages) offers a powerful platform to study human macrophage biology, understand human disease, and develop novel therapies.

- Induced pluripotent stem cell–derived macrophages show similar phenotypic, functional and transcriptomic characteristics as human monocyte-derived macrophages.
- In vitro hematopoietic differentiation of pluripotent stem cells resembles in vivo primitive hematopoiesis rather than adult definitive hematopoiesis. Protocols that specifically differentiate induced pluripotent stem cells to microglia-like cells have been reported.
- Future studies will focus on automation of induced pluripotent stem cell–derived macrophages differentiation, via both primitive and definitive hematopoiesis, with high scalability and reproducibility to produce the full range of myeloid cells that have tissue-specific properties for use in tissue engineering, functional genomic analyses, drug testing, and cell therapeutics.

Highlights
Human Induced Pluripotent Stem Cell–Derived Macrophages for Unraveling Human Macrophage Biology
Hanrui Zhang and Muredach P. Reilly

Arterioscler Thromb Vasc Biol. 2017;37:2000-2006; originally published online October 5, 2017;
doi: 10.1161/ATVBAHA.117.309195

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/37/11/2000

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/